signifor 0.9 mg 1 ml
medison pharma ltd - pasireotide as diaspartate - solution for injection - pasireotide as diaspartate 0.9 mg/ml - pasireotide - pasireotide - treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.
signifor- pasireotide injection
recordati rare diseases, inc. - pasireotide (unii: 98h1t17066) (pasireotide - unii:98h1t17066) - signifor is indicated for the treatment of adult patients with cushing's disease for whom pituitary surgery is not an option or has not been curative. none. risk summary the limited data with signifor in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. in embryo-fetal development studies in rabbits, findings indicating developmental delay were observed with subcutaneous administration of pasireotide during organogenesis at doses less than the exposure in humans at the highest recommended dose; maternal toxicity was not observed at this dose (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. data animal data in embryo-fetal development studies in rats given 1, 5, and 10 mg/kg/day subcutaneously throughout org
signifor 20mg powder and solvent for suspension for injection vials
novartis pharmaceuticals uk ltd - pasireotide pamoate - powder and solvent for suspension for injection - 20mg
signifor 40mg powder and solvent for suspension for injection vials
novartis pharmaceuticals uk ltd - pasireotide pamoate - powder and solvent for suspension for injection - 40mg
signifor 60mg powder and solvent for suspension for injection vials
novartis pharmaceuticals uk ltd - pasireotide pamoate - powder and solvent for suspension for injection - 60mg
signifor lar 20mg powder and solvent for suspension for injection
fta healthcare sdn. bhd. - pasireotide pamoate -
signifor lar 40mg powder and solvent for suspension for injection
fta healthcare sdn. bhd. - pasireotide pamoate -
signifor lar 60mg powder and solvent for suspension for injection
fta healthcare sdn. bhd. - pasireotide pamoate -
signifor lar 20mg powder and solvent for suspension for injection (im)
novartis healthcare philippines, inc.; distributor: novartis healthcare philippines, inc. - pasireotide (as pamoate) - powder and solvent for suspension for injection (im) - 20mg
signifor lar 40mg powder and solvent for suspension for injection (im)
novartis healthcare philippines, inc.; distributor: novartis healthcare philippines, inc. - pasireotide (as pamoate) - powder and solvent for suspension for injection (im) - 40mg